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Abstract
Background: Endothelin 1 (ET-1) is a strong vasoconstrictor, which is involved in inflammation and reduced tissue
perfusion. C-terminal proendothelin-1 (CT-proET-1) is the stable circulating precursor protein of ET-1. We
hypothesized that CT-proET-1, reflecting ET-1 activation, is involved in the pathogenesis of critical illness and
associated with its prognosis.
Methods: Two hundred seventeen critically ill patients (144 with sepsis, 73 without sepsis) were included
prospectively upon admission to the medical intensive care unit (ICU), in comparison to 65 healthy controls.
CT-proET-1 serum concentrations were correlated with clinical data and extensive laboratory parameters. Overall
survival was followed for up to 3 years.
Results: CT-proET-1 serum levels at admission were significantly increased in critically ill patients compared to
controls. CT-proET-1 serum levels showed significant correlations to systemic inflammation as well as multiple
markers of organ dysfunction (kidney, liver, heart). Patients with sepsis displayed higher circulating CT-proET-1 than
ICU patients with non-septic diseases. CT-proET-1 levels >74 pmol/L at ICU admission independently predicted ICU
death (adjusted hazard ratio (HR) 2.66, 95% confidence interval (CI) 1.30–5.47) and overall mortality during follow-up
(adjusted HR 2.19, 95%-CI 1.21–3.98).
Conclusions: CT-proET-1 serum concentrations at admission are increased in critically ill patients and associated
with sepsis, disease severity, organ failure, and mortality.
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Background
Endothelial dysfunction plays an important role in crit-
ical illness, especially in sepsis. It mediates hemodynamic
disturbances based on the vasotonus, contributes to the
balance of pro- and anti-inflammation, regulates nutri-
ent supply and cell migration into tissue, and plays a key
role in host-pathogen interaction [1]. Besides other me-
diators such as nitric oxide (NO), endothelin-1 (ET-1) is
one of the major endogenous factors controlling vasoto-
nus that is released from activated endothelial cells. It is
the most prominent member of the endothelin family. It
binds to two G-protein-coupled receptors, ETA and ETB.
ETA promotes potent vasoconstriction and cell growth,
whereas ETB leads to vasodilation and inhibits cell pro-
liferation [2]. Besides in blood vessels, ET-1-receptors
are also found in tissues, e.g., cardiomyocytes and glom-
erular capillaries [3]. Endothelin release from endothelial
cells is known to be stimulated by bacterial endotoxin
[4] and various inflammatory cytokines such as TNF-
alpha [3] or interleukin-6 [5] as well as mechanical fac-
tors like reduced shear stress [6].
Consecutively, increased levels of endothelin were found
both in animal models of sepsis [7, 8] and human patients
with sepsis [9–11]. Moreover, the function of many organs
(e.g., liver, lung, heart, or kidney) worsens severely after
infusion of ET-1 in animal models [12, 13]. In the past,
* Correspondence: lbuendgens@ukaachen.de
1Department of Medicine III, RWTH-University Hospital Aachen,
Pauwelsstrasse 30, 52074 Aachen, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Buendgens et al. Journal of Intensive Care  (2017) 5:25 
DOI 10.1186/s40560-017-0219-y
various smaller studies could relate these findings to the
clinical outcome of patients and demonstrated a relation
between ET-1 and mortality in sepsis or septic shock in
adults [9, 14, 15] and children [16]. ET-1 itself, however, is
difficult to measure due to its limited half-life. Conse-
quently, sample sizes of trials investigating ET-1 tend to
be relatively small. The precursor peptide C-terminal
proendothelin-1 (CT-proET-1) is far more stable and
allows a stoichiometric measurement of ET-1 [17]. This
facilitates the analysis of larger group of patients as well as
the practical use of this potential biomarker in clinical
routine. We therefore investigated CT-proET-1 in a large
cohort of 217 consecutively enrolled critically ill patients,
including 144 subjects with sepsis, in order to identify as-
sociations between CT-proET-1 and organ dysfunction,
disease severity as well as ICU, and survival during follow-
up in critically ill patients.
Methods
Study design
Written informed consent was obtained from the pa-
tient, his or her spouse, or the appointed legal guardian.
Patients who were expected to have a short (<3 days) in-
tensive care treatment (e.g., due to post-interventional
observation or intoxication) were excluded [18]. The
long-term course of patients was assessed by directly
contacting the patient, the patients’ relatives, or their
primary care physician. We used the third international
consensus definitions for sepsis and septic shock (sepsis-
3) as a post hoc definition for sepsis patients, and all
others were classified as non-sepsis patients [19]. For
identifying and classifying patients with an acute respira-
tory distress syndrome (ARDS), we used the Berlin
definition of ARDS [20].
Sixty-five healthy blood donors with normal values for
blood counts, C-reactive protein, and liver enzymes served
as controls. The study protocol was approved by the local
ethics committee and conducted in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki (ethics committee of the University Hospital Aa-
chen, RWTH-University, Aachen, Germany, reference
number EK 150/06). The current study was part of a lar-
ger assessment of biomarkers in critically ill patients, con-
ducted between 2006 and 2014 at our center.
CT-proET-1 measurements
Blood samples were collected directly upon admission of
the patient to the ICU prior to therapeutic interventions
at the ICU. After centrifugation at 4 °C for 10 min,
serum aliquots of 1 mL were frozen immediately at
−80 °C. CT-proET-1 serum concentrations were mea-
sured using a commercially available fluorescent im-
munoassay (BRAHMS GmbH/ThermoFischer Scientific,
Henningsdorf, Germany) following the manufacturer’s
protocol. The scientist performing laboratory measure-
ments was fully blinded to any clinical or other labora-
tory data of the patients or controls.
Statistical analysis
Data are displayed as median and range due to the
skewed distribution of most of the parameters. Differ-
ences between two groups were assessed by Mann-
Whitney U test or chi-squared test. Differences between
multiple groups were assessed using the Kruskal-Wallis
test. To illustrate differences between subgroups, box
plot graphics were used displaying a summary of the
median, quartiles, range, and extreme values of the given
data. Their whiskers range from the minimum to the
maximum value excluding outliers displayed as separate
points. An outlier was defined as a value that is smaller
than the lower quartile minus 1.5 times the interquartile
range or larger than the upper quartile plus 1.5 times
the interquartile range. A far-out value was defined as a
value that is smaller than the lower quartile minus three
times the interquartile range or larger than the upper
quartile plus three times the interquartile range [21].
Correlations between variables were assessed with Spear-
man correlation tests. The Cox regression model was
used for univariate and multivariate analysis of risk fac-
tors. Kaplan-Meier curves were used to illustrate differ-
ences in survival [22]. Differences between the groups
regarding survival were assessed with the log-rank test.
Receiver operating characteristic (ROC) curve analysis
were used to evaluate the value of a predictive marker or
a composite score. ROC curves were generated by plot-
ting sensitivity against 1-specificity [23]. Differences be-
tween ROC curves were assessed using the method
described by DeLong et al. [24]. Statistical analyses were
performed with SPSS Version 23 (SPSS, Chicago, IL,
USA) and MedCalc Version 16 (MedCalc Software,
Ostend, Belgium).
Results
CT-proET-1 serum concentrations are increased in
critically ill patients and associated with sepsis
In order to investigate the role of CT-proET-1 in critical
illness, we measured serum levels in 217 patients at the
time of admission to our medical ICU. In comparison to
65 healthy controls, CT-proET-1 levels were strongly el-
evated in critically ill patients (median 5.8 vs 65.4 pmol/
L, p < 0.001, U test; Fig. 1a).
Of all 217 patients, 144 were admitted because of sepsis.
The most frequent septic focus was pneumonia (n = 74),
followed by abdominal (n = 26) and urogenital infections
(n = 11) (detailed data not shown). Non-septic ICU pa-
tients were admitted due to cardio-pulmonary diseases (n
= 29), pancreatitis (n = 12), decompensated liver cirrhosis
(n = 9), and other non-septic diseases (n = 23). CT-proET-
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1 levels were significantly higher in patients with sepsis
compared to other ICU patients (median 40.9 vs 82.1
pmol/L; p < 0.001; Fig. 1b, Table 1). Sepsis and non-sepsis
patients did not differ in age or sex, but sepsis patients
had significantly higher APACHE-II or SOFA scores, in-
creased mortality, longer stay on the ICU, and an in-
creased vasopressor demand (Table 1). In order to exclude
that the difference in CT-pro-ET1 was related to the
presence of sepsis and not to disease severity, the non-
sepsis ICU patients were matched 1:1 with a patient from
the sepsis group for APACHE-II score (disease severity),
age, and sex. In this subanalysis, CT-pro-ET1 remained
indeed higher in the sepsis group (p < 0.001; Fig. 1c).
To investigate a possible use of CT-proET-1 in identi-
fying patients with sepsis, we conducted a ROC curve
analysis comparing CT-proET-1 to other, established
Fig. 1 Serum CT-proET-1 concentrations in critically ill patients and sepsis. a Serum levels of CT-proET-1, at the time of admission to the ICU, were
significantly higher in critically ill patients than in healthy controls (p < 0.001; U test). b CT-proET-1 levels were significantly higher in patients with
sepsis (p < 0.001) compared to ICU patients without sepsis. c When matched 1:1 with non-sepsis patients for APACHE-II score, age, and sex,
CT-proET-1 levels were significantly higher in patients with sepsis compared to ICU patients without sepsis (p < 0.001)
Table 1 Baseline patient characteristics and CT-proET-1 serum measurements at ICU admission
Parameter All patients Sepsis Non-sepsis pa
Number 217 144 73
Sex (male/female) 132/85 84/60 48/25 n.s.
Age median, (range) [years] 64 (18–90) 65 (20–90) 61 (18–85) n.s.
APACHE-II score, median (range) 18 (2–43) 19 (4–43) 14 (2–33) <0.001
SOFA score, median (range) 9 (0–17) 9 (2–17) 7 (0–17) 0.003
SAPS 2 score, median (range) 41 (0–73) 40 (0–73) 41 (0–73) 0.193
Mechanical ventilation, n (%) 144 (69) 98 (63) 46 (63) n.s.
Ventilation time, median (range) [h] 117 (0–3828) 125.5 (0–2966) 66 (0–2828) n.s.
Vasopressor demand, n (%) 132 (60.8) 99 (68.8) 33 (45.2) <0.001
ICU days, median (range) 7 (1–137) 8.5 (1–137) 6 (1–45) 0.004
30-day mortality, n (%) 41 (18.9) 34 (23.6) 7 (9.6) 0.016
Overall mortality, n (%) 86 (41.7) 64 (46.7) 22 (31.9) 0.42
CT-proET-1, median (range) [pmol/L] 43.8 (3–503.6) 82.1 (3–503.6) 40.9 (3–372.9) <0.001
Leucocytes, median (range) [per nL] 12.9 (0.5–208) 13.8 (0.5–208) 12.5 (1.8–29.6) 0.041
CRP, median (range) [mg/L] 98 (5–230) 160.5 (5–230) 17 (5–230) <0.001
Cystatin C, median (range) [mg/L] 1.48 (0.39–8.38) 1.69 (0.39–8.38) 1.04 (0.56–2.29) <0.001
Bilirubin, median (range) [per mg/dL] 0.7 (0.2–20.8) 0.7 (0.2–6.8) 0.7 (0.2–20.8) n.s.
For quantitative variables, median and range (in parenthesis) are given
Abbreviations: CRP C-reactive protein, CT-proET-1 C-terminal proendothelin-1, APACHE Acute Physiology and Chronic Health Evaluation, SAPS 2 Simplified Acute
Physiology Score, SOFA Sequential Organ Failure Assessment, n.s. not significant
aSignificance between sepsis and non-sepsis patients was assessed using the Mann-Whitney U test or chi-squared test
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markers (procalcitonin and C-reactive protein (CRP)).
With an AUC of 0.834 (95%-CI 0.768–0.900), CRP was
significantly superior to both PCT (p = 0.046; DeLong
test) and CT-proET-1 (p = 0.007; DeLong test). Interest-
ingly, CT-proET-1 was non-inferior to PCT (AUC 0.704
vs 0.757; p = 0.24; DeLong test).
CT-proET-1 levels in critically ill patients correlate with
clinical disease severity scores and organ dysfunction
Based on the pathogenic role of endothelin-1 for vasocon-
striction and impaired tissue perfusion [25], we hypothe-
sized that increased CT-proET-1 might be associated with
organ dysfunction in ICU patients. Strikingly, CT-proET-1
levels were strongly associated with markers of renal dys-
function (e.g., creatinine, r = 0.500, p < 0.001; cystatin C, r
= 0.624, p < 0.001), cholestasis (e.g., bilirubin, r = 0.148, p
= 0.031), impaired hepatic synthesis (e.g., albumin, r =
−0.321, p = 0.001; pseudocholinesterase, r = −0.438, p <
0.001; prothrombin time, r = −0.220, p = 0.001) and car-
diac failure (e.g., brain natriuretic peptide, r = 0.505, p <
0.001). Likewise, CT-proET-1 levels correlated with
markers of general inflammation (e.g., C-reactive protein,
r = 0.416, p < 0.001, Table 2).
Interestingly, patients with manifest organ failure had
significantly elevated CT-proET-1 levels. This was ob-
served for patients with renal failure (defined as a cysta-
tin C-based glomerular filtration rate below 50 mL/min,
Fig. 2a), liver failure (defined as prothrombin time <50%,
Fig. 2b), or heart failure (defined as a NTproBNP
>1000 pg/ml; Fig. 2c). As prior studies reported elevated
ET-1 in patients with ARDS compared to controls [26],
we further assessed CT-proET-1 serum levels in regard
to the degree of an ARDS. However, CT-proET-1 did
not differ between ICU patients without ARDS (n = 22)
and with mild (n = 29), moderate (n = 27), or severe (n =
13) ARDS at the time of admission (Fig. 2d).
Additionally, CT-proET-1 levels were associated with
severity of critical illness. Patients with higher APACHE-II
(above 18) and SAPS 2 (above the median of the cohort)
scores showed significantly increased serum levels of CT-
proET-1 (Fig. 3a, b). CT-proET-1 also positively correlated
with these disease severity scores (APACHE-II, r = 0.239,
p = 0.001; SAPS 2, r = 0.400, p < 0.001, Table 2). CT-
proET1 did not correlate with the SOFA score, neither for
all nor for sepsis patients (detailed data not shown).
CT-proET-1 at admission is an independent predictor of
ICU mortality
As CT-proET-1 levels correlate with organ dysfunction
and disease severity, we hypothesized that CT-proET-1
serum concentrations at the time of ICU admission might
be associated with mortality in critically ill patients. Over-
all, n = 41 (18.9%) of the patients died at the ICU, while n
= 86 (39.6%) died overall including the follow-up time (of
up to 3 years). Remarkably, patients that died at the ICU
showed significant higher serum levels of CT-proET-1 at
ICU admission than survivors (median 88.3 vs 59.2 pmol/
L; p = 0.029; Fig. 4a).
By Cox regression analysis, CT-proET-1 levels were
found to predict ICU mortality (p = 0.047). We used the
Youden index (28) to find the best cut-off value regarding
sensitivity and specificity. Based on the coordinates of the
ROC curve, a CT-proET-1 cut-off value of 74 pmol/L
showed the best ratio of sensitivity and specificity in pre-
dicting ICU mortality. Interestingly, this value is higher
than the measurements of our healthy controls and repre-
sents the 99th percentile of a healthy population. Kaplan-
Meier survival curve analysis confirmed that high CT-
proET-1 levels were strongly associated with 30-day mor-
tality (Fig. 4b; p = 0.002). As CT-proET-1 correlates with
markers of organ failure, excretion and inflammation, we
next tested if CT-proET-1 serum levels can independently
predict survival. We performed uni- and multivariate Cox
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Abbreviations: ALT alanine aminotransferase, APACHE Acute Physiology and Chronic
Health Evaluation, ALT alanine aminotransferase, CRP C-reactive protein, GFR
glomerular filtration rate, IL6 interleukin 6, NTproBNP amino-terminal propeptide of
brain natriuretic peptide, NTproCNP, amino-terminal propeptide of C-type natriuretic
peptide, SAPS Simplified Acute Physiology Score, SOFA sequential organ failure
assessment, suPAR soluble urokinase plasminogen activator receptor, n.s.
not significant
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regression analysis including age, markers of inflammation
(i.e., CRP), renal (i.e., creatinine), circulatory (i.e., lactate),
and hepatic dysfunction (i.e., bilirubin, prothrombin time).
Here, high CT-proET-1 (>74 pmol/L) was an independent
predictor of ICU mortality in critically ill patients (ad-
justed hazard ratio (HR) 2.66 (95% CI 1.30–5.47), Table 3).
High levels of CT-proET-1 at ICU admission are associated
with overall survival
Given its association with short-term mortality, we ex-
amined if the level of CT-proET-1 at admission to the
ICU was also related to long-term outcome. We found
that CT-proET-1 levels were significantly higher in pa-
tients that died during the follow-up period compared to
the overall surviving patients (median 53.7 vs 89.9 pmol/
L; p = 0.003; Fig. 5a).
Again, Kaplan-Meier analysis showed a good discrimin-
ation in terms of long-term survival between the groups
with high and low CT-proET-1 values (Fig. 5b, p < 0.001).
In addition, we conducted uni- and multivariate Cox re-
gression analyses including age, markers of inflammation
(i.e., CRP) and renal (i.e., creatinine), circulatory (i.e., lactate),
Fig. 2 Serum CT-proET-1 levels in critically ill patients are associated with organ failure. a–c Serum levels of CT-proET-1 at the time of admission
to the ICU were significantly higher in critically ill patients with renal (cystatin C-based glomerular filtration rate (GFR) <50 mL/min; p < 0.001, U
test), hepatic (prothrombin time <50%; p = 0.016) or cardiac failure (NTproBNP >1000 pg/mL; p < 0.001). d CT-proET-1 was not associated with the
presence or severity of an acute respiratory distress syndrome (p = 0.715, Kruskal-Wallis test)
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and hepatic dysfunction (i.e., bilirubin, prothrombin time)
(Table 4). Adjusted by the factors above high CT-proET-1
(>74 pmol/L) remained an independent predictor of overall
survival (adjusted HR 2.19, 95%-CI 1.21–3.98).
Discussion
In this study, we demonstrate striking regulations of circu-
lating CT-proET-1 in a large cohort of critically ill patients,
supporting our hypothesis to use this stoichiometric indica-
tor of ET-1 as a diagnostic and prognostic biomarker in in-
tensive care medicine. We could show that CT-proET-1 is
significantly elevated in critically ill patients compared to
healthy controls, correlates with disease severity and organ
failure, and is an independent risk predictor for ICU and
overall mortality.
Previous smaller studies [9, 14, 15] had reported an as-
sociation of CT-proET-1 with short-term mortality in pa-
tients with sepsis. In contrast, one study on 99 sepsis
patients that measured CT-proET-1 within 48 h after ad-
mission did not reproduce the relation between CT-
proET-1 and mortality risk [27]. Very recently, Lundberg
and colleagues reported that elevated CT-proET-1 levels
at ICU admission were associated with 7-day and 28-day
mortality in 53 patients with septic shock [14]. Our study
now extends these prior findings to a more heteroge-
neous, larger prospective cohort of medical ICU patients
demonstrating a clear prognostic value of circulating CT-
Fig. 3 Serum CT-proET-1 levels in critically ill patients are associated with disease severity. Critically ill patients with higher disease severity as
represented by APACHE-II (a), SAPS 2 (b) showed significantly higher CT-proET-1 levels, while SOFA score (c) was unrelated to CT-proET-1
Fig. 4 Prediction of ICU mortality by CT-proET-1 serum levels. a Patients that died during the course of ICU treatment had significantly higher serum
CT-proET-1 levels on admittance to ICU (p < 0.001; U test) than survivors. b Kaplan-Meier survival curves of ICU patients are displayed for the 30-day
mortality, showing that patients with CT-proET-1 below a cut-off value of 74 pmol/L had a better outcome at the ICU (p = 0.002; log-rank test)
Buendgens et al. Journal of Intensive Care  (2017) 5:25 Page 6 of 9
proET-1. While patients with sepsis had higher CT-
proET-1 levels than ICU patients with non-septic disease,
CT-proET-1 at ICU admission predicted 30-day mortality
for the total patient cohort as well as for sepsis or non-
sepsis patients. Moreover, we found that CT-proET-1
levels at ICU admission were even indicative of the long-
term mortality risk, based on follow-up observations of
about 3 years. This effect of CT-proET-1 on ICU and
overall mortality was independent from single markers of
organ failure or inflammation, indicating that CT-proET-1
could be useful in clinical algorithms or scores aiming at
identifying high-risk patients upon ICU admission.
A prior study by Druml et al. found an association be-
tween ET-1 and the presence of an ARDS [26]. We did
not observe such an association, but our study population
was considerably different. While our cohort included a
rather heterogeneous population of medical ICU patients
with and without sepsis, Druml et al. specifically investi-
gated ARDS patients in comparison to healthy controls,
presumably with fewer confounding comorbidities than in
our patient population.
Moreover, our findings might also provide important
insights into the role of ET-1 (measured by CT-proET-1)
in the pathogenesis of critical illness. The serum levels
of CT-proET1 correlated with organ dysfunction and
disease severity, but not with lactate, a marker of shock
and circulatory failure. Thus, CT-proET1 reflects not a
just mere hypoperfusion of tissues due to circulatory
failure, but a more complex endothelial activation or
dysfunction related to organ failure.
Nonetheless, our exploratory study has several limita-
tions. These include the single center setting with the
retrospective assessment of CT-proET1 in a prospect-
ively enrolled study cohort. Moreover, we do not have
Table 3 Uni- and multivariate Cox regression analyses for CT-proET-1 levels at ICU admission to predict ICU mortality
Unadjusted HR (95%-CI) p Adjusted HR (95%-CI) p
CT-proET-1 > 74 pmol/L 2.658 (1.375–5.137) 0.004 2.663 (1.296–5.470) 0.008
Creatinine (per mg/dL) – n.s.
CRP (per mg/L) – n.s.
Bilirubin (per mg/dL) 1.129 (1.021–1.249) 0.018 – n.s.
Prothrombin time (per %) 0.988 (0.977–1) 0.045 – n.s.
Lactate (per mmol/L) 1.115 (1.03–1.207) 0.007 1.20 (1.109–1.298) <0.001
Age (per year) 1.034 (1.011–1.058) 0.003 1.045 (1.019–1.71) 0.003
Variables with an univariate p < 0.25 were included in the multivariate model
Abbreviations: 95%-CI, 95% confidence interval, CRP C-reactive protein, CT-proET-1 C-terminal proendothelin-1, n.s. not significant
Fig. 5 Prediction of overall mortality by CT-proET-1 serum concentrations. a Patients that died during the total observation period had significantly
higher serum CT-proET-1 levels at ICU admission than survivors (p < 0.001; U test). b Kaplan-Meier survival curves of ICU patients are displayed, showing
that patients with CT-proET-1 levels above a cut-off of 74 pmol/L have an increased overall mortality (p < 0.001; log-rank test)
Buendgens et al. Journal of Intensive Care  (2017) 5:25 Page 7 of 9
longitudinal measurements of CT-proET1, which could
potentially improve the prognostic validity of this
marker. Also, organ failure assessment was solely based
on laboratory parameters, but no functional tests (like
echocardiography or liver biopsy).
However, the hyperactivation of ET-1 in our cohort of
ICU patients and the strong association of ET-1 with organ
dysfunction and mortality indicate that ET-1 might be a
potential drug target in critical illness and sepsis. It is
tempting to speculate that antagonizing systemic supra-
physiological ET-1 levels holds therapeutic potential to
improve tissue perfusion. In fact, the endothelin receptor
antagonist bosentan has shown positive effects on tissue
perfusion [28, 29] and cardiac output [30, 31] in animal
models of septic shock. Moreover, the application of
bosentan in a rodent model of septic shock was even able
to improve survival [32]. Interestingly, this effect was more
pronounced, if bosentan was given in the hypodynamic
stage after fluid resuscitation, a disease stage where specific
treatment options are currently scarce. Our data corrobor-
ate to further investigate ET-1-antagonistic approaches in
the ICU setting, in order to define the efficacy as well as
optimal dose and timing for such an intervention.
Conclusions
Our study shows that CT-proET-1 is elevated in critically
ill patients and in sepsis. It is associated with organ dys-
function and poses an independent risk factor for ICU and
overall mortality. The potential as a drug treatment target
in critically ill patients requires further investigations.
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Key messages
CT-proET-1 is a stoichiometric surrogate of the potent endogenous
vasoconstrictor endothelin-1 (ET-1).
CT-proET-1 is significantly elevated in critically ill patients (n = 217) at
admission to the ICU compared with healthy controls (n = 65).
CT-proET-1 is elevated in sepsis compared to non-septic ICU patients and is
associated with systemic inflammation as well as organ failure.
High CT-proET-1 is an independent risk predictor for ICU and overall mortality.
These data imply that CT-proET-1 is a promising prognostic biomarker in
critical illness and that ET-1 could be a novel drug target in the pathogenesis
of sepsis and septic shock.
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Table 4 Uni- and multivariate Cox regression analyses for CT-proET-1 levels at ICU admission to predict overall mortality
Unadjusted HR (95%-CI) p Adjusted HR (95%-CI) p
CT-proET-1 > 74 pmol/L 2.731 (1.535–4.858) 0.001 2.193 (1.209–3.975) 0.01
Creatinine (per mg/dL) 1.034 (0.946–1.129) 0.461 – n.s.
CRP (per mg/L) 1.002 (0.999–1.006) 0.129 – n.s.
Bilirubin (per mg/dL) 1.16 (0.935–1.16) 0.176 – n.s.
Prothrombin time (per %) 0.99 (0.979–1) 0.052 – n.s.
Lactate (per mmol/L) 1.082 (0.949–1.234) 0.239 – n.s.
Age (per year) 1.036 (1.014–1.059) <0.001 1.028 (1.005–1.051) 0.04
Variables with a univariate p < 0.25 were included in the multivariate model
Abbreviations: 95%-CI 95% confidence-interval, CRP C-reactive protein, CT-proET-1 C-terminal proendothelin-1, n.s. not significant
Buendgens et al. Journal of Intensive Care  (2017) 5:25 Page 8 of 9
Received: 20 August 2016 Accepted: 2 March 2017
References
1. Aird WC, Rangel-Frausto M, Pittet D, Costigan M, Bone R, Balk R, et al. The
role of the endothelium in severe sepsis and multiple organ dysfunction
syndrome. Blood. 2003;101:3765–77.
2. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy.
Can J Physiol Pharmacol. 2008;86:485–98.
3. Hynynen MM, Khalil RA. The vascular endothelin system in
hypertension—recent patents and discoveries. Recent Pat Cardiovasc Drug
Discov. 2006;1:95–108.
4. Sugiura M, Inagami T, Kon V. Endotoxin stimulates endothelin-release in
vivo and in vitro as determined by radioimmunoassay. Biochem Biophys
Res Commun. 1989;161:1220–7.
5. Yamashita J, Ogawa M, Nomura K, Matsuo S, Inada K, Yamashita S, et al.
Interleukin 6 stimulates the production of immunoreactive endothelin 1 in
human breast cancer cells. Cancer Res. 1993;53:464–7.
6. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, et
al. Hemodynamic shear stress stimulates endothelin production by cultured
endothelial cells. Biochem Biophys Res Commun. 1989;161:859–64.
7. Kaddoura S, Curzen NP, Evans TW, Firth JD, Poole-Wilson PA. Tissue
expression of endothelin-1 mRNA in endotoxaemia. Biochem Biophys Res
Commun. 1996;218:641–7.
8. Kaszaki J, Wolfárd A, Boros M, Baranyi L, Okada H, Nagy S. Effects of
antiendothelin treatment on the early hemodynamic changes in
hyperdynamic endotoxemia. Acta Chir Hung. 1997;36:152–3.
9. Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor
necrosis factor-α: early predictors of mortality in patients with septic shock.
Intensive Care Med. 2000;26:305–13.
10. Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin
in patients with sepsis syndrome. Circ Shock. 1991;33:222–7.
11. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, et al.
Elevated plasma endothelin-1 concentrations are associated with the
severity of illness in patients with sepsis. Ann Surg. 1991;213:261–4.
12. Fenhammar J, Andersson A, Forestier J, Weitzberg E, Sollevi A, Hjelmqvist H,
et al. Endothelin receptor A antagonism attenuates renal medullary blood
flow impairment in endotoxemic pigs. PLoS One. 2011;6:e21534.
13. Piechota-Polańczyk A, Gorąca A. Influence of specific endothelin-1 receptor
blockers on hemodynamic parameters and antioxidant status of plasma in
LPS-induced endotoxemia. Pharmacol Reports. 2012;64:1434–41.
14. Lundberg OHM, Bergenzaun L, Rydén J, Rosenqvist M, Melander O, Chew
MS. Adrenomedullin and endothelin-1 are associated with myocardial injury
and death in septic shock patients. Crit Care. 2016;20:178.
15. Schuetz P, Christ-Crain M, Morgenthaler NG, Struck J, Bergmann A, Müller B.
Circulating precursor levels of endothelin-1 and adrenomedullin, two
endothelium-derived, counteracting substances, in sepsis. Endothelium.
2008;14:345–51.
16 Rey C, García-Hernández I, Concha A, Martínez-Camblor P, Botrán M, Medina
A, et al. Pro-adrenomedullin, pro-endothelin-1, procalcitonin. C-reactive
protein and mortality risk in critically ill children: a prospective study. Crit
Care. 2013;17:R240.
17 Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A.
Immunoluminometric assay for measurement of the C-terminal endothelin-
1 precursor fragment in human plasma. Clin Chem. 2006;52:1144–51.
18 Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C, Van Cromphaut S, et
al. Serum resistin levels in critically ill patients are associated with
inflammation, organ dysfunction and metabolism and may predict survival
of non-septic patients. Crit Care. 2009;13:R95.
19 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer
M, et al. The third international consensus definitions for sepsis and septic
shock (sepsis-3). Jama. 2016;315:801–10.
20 The ARDS Definition Task Force. Acute respiratory distress syndrome. J. Am.
Med. Assoc. 2012;307:1.
21 Koch A, Sanson E, Voigt S, Helm A, Trautwein C, Tacke F. Serum adiponectin
upon admission to the intensive care unit may predict mortality in critically
ill patients. J Crit Care. 2011;26:166–74.
22 Koch A, Voigt S, Sanson E, Duckers H, Horn A, Zimmermann HW, et al.
Prognostic value of circulating amino-terminal pro-C-type natriuretic
peptide in critically ill patients. Crit Care. 2011;15:R45.
23 Koch A, Sanson E, Helm A, Voigt S, Trautwein C, Tacke F. Regulation and
prognostic relevance of serum ghrelin concentrations in critical illness and
sepsis. Crit Care. 2010;14:R94.
24 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44:837–45.
25 Wu R, Dong W, Zhou M, Cui X, Simms HH, Wang P. Ghrelin improves tissue
perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc
Res. 2005;68:318–26.
26 Druml W, Steltzer H, Waldhausl W, Lenz K, Hammerle A, Vierhapper H, et al.
Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis.
1993;148:1169–73.
27 Guignant C, Venet F, Voirin N, Poitevin F, Malcus C, Bohé J, et al. Proatrial
natriuretic peptide is a better predictor of 28-day mortality in septic shock
patients than proendothelin-1. Clin Chem Lab Med. 2010;48:1813–20.
28 Krejci V, Hiltebrand LB, Erni D, Sigurdsson GH. Endothelin receptor
antagonist bosentan improves microcirculatory blood flow in splanchnic
organs in septic shock. Crit Care Med. 2003;31:203–10.
29 Oldner A, Wanecek M, Goiny M, Weitzberg E, Rudehill A, Alving K, et al. The
endothelin receptor antagonist bosentan restores gut oxygen delivery and
reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut. 1998;
42:696–702.
30 Wanecek M, Oldner A, Rudehill A, Sollevi A, Alving K, Weitzberg E.
Cardiopulmonary dysfunction during porcine endotoxin shock is effectively
counteracted by the endothelin receptor antagonist bosentan. Shock. 1997;
7:364–70.
31 Weitzberg E, Hemsén A, Rudehill A, Modin A, Wanecek M, Lundberg JM.
Bosentan-improved cardiopulmonary vascular performance and increased
plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol.
1996;118:617–26.
32 Iskit AB, Senel I, Sokmensuer C, Guc MO. Endothelin receptor antagonist
bosentan improves survival in a murine caecal ligation and puncture model
of septic shock. Eur J Pharmacol. 2004;506:83–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Buendgens et al. Journal of Intensive Care  (2017) 5:25 Page 9 of 9
